Risultati per: JAMA Psychiatry

Mission Statement: JAMA Dermatology’s mission is to elevate the art and science of health and diseases of skin, hair, nails, and mucous membranes, and their treatment, to enable dermatologists to deliver evidence-based, high-value medical and surgical dermatologic care. The journal publishes a broad range of innovative studies and trials that shift research and clinical practice paradigms, expand the understanding of the burden of dermatologic diseases and key outcomes, improve the practice of dermatology, and ensure equitable care to all patients. The journal also features research and opinion examining ethical, moral, socioeconomic, educational, and political issues relevant to dermatologists to enable ongoing improvement to the workforce, scope of practice, and the training of future dermatologists. JAMA Dermatology aims to be a leader in developing initiatives to improve diversity, equity, and inclusion within the specialty and within dermatology medical publishing.

Mission Statement: JAMA Psychiatry strives to publish original, state-of-the-art studies and commentaries of general interest to clinicians and researchers in psychiatry, mental health, behavioral science, and allied fields. The journal seeks to inform its readers, to stimulate discussion into the nature, causes, treatment, and public health importance of mental illness, and to promote equity and justice for those affected by mental illness and for society.

JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.

Mission Statement: To advance the equitable, person-centered, and evidence-based practice of internal medicine through publication of scientifically rigorous, innovative, and inclusive research, review, and commentary that informs dialogue and action with clinical, public health, and policy impact.

How people consume information is evolving. So is JAMA Medical News. This issue debuts JAMA Data Brief, a new department in the journal’s long-standing Medical News & Perspectives.

We sincerely thank the 878 peer reviewers who completed manuscript reviews for JAMA Oncology in 2023.

We sincerely thank the 657 peer reviewers who completed manuscript reviews for JAMA Dermatology in 2023.

Over the past year, JAMA editors have been developing the concept of the JAMA Summit—forums for catalyzing discussion and action on pressing issues in science, medicine, and public health. Over its more than 140-year history, JAMA has been a leader in publishing on critical issues related to health. As a forum for eliciting new ideas, facilitating cross-sector dialogue, and identifying opportunities for progress that inspire discussion and action, the JAMA Summit represents the latest iteration of this long tradition of furthering our mission to advance the science and art of medicine and the betterment of public health.

We sincerely thank the 646 peer reviewers who completed manuscript reviews for JAMA Internal Medicine in 2023.

We live in a tumultuous time of increased health care challenges within a milieu of ongoing COVID-19, climate change, war, gun violence, racial and ethnic discrimination, political divisions, and ongoing financial challenges to health care systems and financing. Amidst this background, the JAMA Internal Medicine editors came together to renew our commitment to publishing evidence to inform and improve health and health care. Our commitment is captured in our new mission statement: “To advance the equitable, person-centered, and evidence-based practice of internal medicine through publication of scientifically rigorous, innovative, and inclusive research, review, and commentary that informs dialogue and action with clinical, public health, and policy impact.”

2023 Was another exceptional year for JAMA Dermatology. The editorial team evaluated a steady number of article submissions (Table). A total of 956 of 2756 submissions were research articles. Acceptance rates remained stable, with 10% of submissions overall and 11% of research articles accepted for publication. The journal continued to maintain its goal of reducing the time to publication, keeping the median days of acceptance to publication to 63 days while offering timely editorial decisions, including maintaining the median time to first decision without peer review to 4 days. The median time of receipt to first decision with peer review increased slightly to 63 days, highlighting an area for process improvement aligned with our commitment to publishing excellence. JAMA Dermatology’s Journal Impact Factor remained high at 10.9.